Search Results
Your search for all items matches 34736 pages
Showing 21601 - 21650Preclinical Study Finds SPOP Mutation Drives Prostate Cancer Subtype
A genetically engineered mouse model developed by Blattner et al investigating the role of the gene Speckle Type BTB/POZ Protein, or SPOP, as a driver of prostate cancer has found that the mutation drives prostate neoplasia through coordinate deregulation of both P13K/mTOR and androgen receptor...
ACC.17: History of Exercise Helps Prevent Heart Disease After Breast Cancer
Regular exercise appears to help mitigate the increased cardiovascular risk faced by women treated for breast cancer, according to a study scheduled for presentation at the American College of Cardiology's 66th Annual Scientific Session (ACC.17). The study found that women with breast cancer who...
Key Gene Controlling Tumor Growth in Gliomas Pinpointed
Cedars-Sinai investigators have identified a stem cell–regulating gene that affects tumor growth in patients with brain cancer and can strongly influence survival rates of patients. The findings, published by Edwards et al in Nature Scientific Reports, could move physicians closer to their...
Use of Evidence-Based Prostate Cancer Imaging in an Integrated Health-Care System
In a study reported in the Journal of Oncology Practice, Salloum et al found that use of nonindicated imaging for diagnostic staging of low-risk prostate cancer in a nonprofit integrated health-care system remained common but has decreased in frequency. As noted by the authors: “The overuse...
Dutch Study Examines Effect of Internet-Based Cognitive Behavioral Therapy on Sexual Functioning in Breast Cancer Survivors
In a Dutch study reported in the Journal of Clinical Oncology, Hummel et al found that use of an Internet-based cognitive behavioral therapy intervention improved sexual functioning among breast cancer survivors. Study Details In the study, 169 women with a diagnosis of sexual dysfunction from 10 ...
UK Trial Shows No Survival Benefit in Adding Pravastatin to Standard Chemotherapy in Small Cell Lung Cancer
In the UK phase III LUNGSTAR study reported in the Journal of Clinical Oncology, Seckl et al found that adding pravastatin to first-line standard chemotherapy did not improve overall survival in patients with small cell lung cancer (SCLC). Numerous large prospective cohort and registry studies...
ASCO Urges Lawmakers to Fund Cancer Research on Capitol Hill
The importance of a strong federal investment in cancer research was front and center at ASCO’s congressional briefing this past month, where the Society presented Clinical Cancer Advances 2017: ASCO’s Annual Report on Progress Against Cancer. In addition to announcing the top cancer advance of the ...
Spotlight: ASCO Clinical Affairs
ASCO is working—through research, education, and promotion of the highest quality patient care—toward a world where cancer is prevented or cured, and every survivor is healthy. With the goal of ensuring that all patients receive the high-quality care they expect and deserve, ASCO is committed to...
Clinical Practice Committee, State Affiliate Council Support Innovative Clinical Research—And So Can You
ASCO’s Clinical Practice Committee (CPC) and State Affiliate Council (SAC) have a history of supporting the Conquer Cancer Foundation of ASCO (CCF) Young Investigator Award (YIA) program. Individual members of the Clinical Practice Committee and State Affiliate Council, as well as ASCO State...
ASCO’s Patient Resources for Colorectal Cancer Awareness Month
Stock your practice with ASCO resources for your patients during March, Colorectal Cancer Awareness Month. Visit ASCO’s patient information website, Cancer.Net, for a comprehensive guide to colorectal cancer as well as a shorter, one-page colorectal cancer fact sheet. You will also find specialized ...
University of Virginia Cancer Center Joins CancerLinQ® as Participating Practice
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has announced that the University of Virginia Cancer Center has signed an agreement to participate in the CancerLinQ ® platform. “As CancerLinQ ® continues to rapidly grow, we are thrilled to have the University of Virginia Cancer Center ...
Ibrutinib in Marginal Zone Lymphoma
On January 19, ibrutinib (Imbruvica) was granted accelerated approved for treatment of patients with marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20–based therapy.1 Supporting Efficacy Data Approval was based on overall response rate in a...
Low-Grade Gliomas: Understanding the New Treatment Paradigm
Diffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas and account for about 5% of all primary brain tumors. Treatment strategies for these low-grade gliomas in adults have recently changed, as detailed in a recent review in the Journal of Oncology Practice.1 The...
Alice T. Shaw, MD, PhD, and Pasi A. Jänne, MD, PhD, Named Co‑Leaders of SU2C-ACS Dream Team on Lung Cancer
Alice T. Shaw, MD, PhD, of Massachusetts General Hospital Cancer Center, and Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, have been named co-leaders of the Stand Up to Cancer (SU2C)-American Cancer Society (ACS) Lung Cancer Dream Team, joining co-leader Jedd Wolchok, MD, PhD, of...
Royal Swedish Academy of Sciences Inaugural Sjöberg Prize Awarded to James P. Allison, PhD, and Tony Hunter, PhD
The Royal Swedish Academy of Sciences (RSAS) has decided to award the inaugural Sjöberg Prize 2017 to James P. Allison, PhD, Professor and Vivian L. Smith Distinguished Chair in Immunology at The University of Texas MD Anderson Cancer Center, and Tony Hunter, PhD, American Cancer Society...
Value-Based Approaches to the Rising Costs of Cancer Drugs
It’s no secret that cancer drug costs have skyrocketed out of control, with some treatments costing as much as $100,000 to $200,000 per year and even upward. This has put tremendous strain on the U.S. health-care system, while causing financial toxicity and bankruptcy for many patients. Peter B....
Expert Point of View: Cornelius J.M. Melief, MD, PhD
Cornelius J.M. Melief, MD, PhD, Emeritus Professor at Leiden University Medical Center in the Netherlands and Chief Scientific Officer at ISA Pharmaceuticals, noted that toll-like receptors (TLRs) are useful in promoting immune activation in a variety of leukocytes and that the signaling pathways...
Novel Immunotherapy Added to Standard Care Did Not Meet Endpoint in Patients With Advanced Head and Neck Cancer
In the phase II Active8 trial, a novel immunotherapy agent, motolimod, failed to improve outcomes over chemotherapy plus cetuximab (Erbitux) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. In a post hoc analysis, however, patients with injection-site...
Scientists Tackle Next Set of Immunotherapy Challenges
Cancer immunotherapy is about to get much more complicated. Just as oncologists are becoming familiar with checkpoint inhibitors and their growing indications, they will eventually be challenged with using them in novel combinations and in new tumor types. This will be the fruit that comes from...
Close to Home: Dr. Rick Boulay’s Experience With Cancer Survivorship and Caregiving
Richard ‘Rick’ Boulay, MDChief of Gynecologic Oncology Institution: Lehigh Valley Health Network Member since: 2016 Three years ago, Richard ‘Rick’ Boulay, MD, Chief of Gynecologic Oncology at Lehigh Valley Health Network, walked onto the stage at TEDx Lehigh River and confronted his audience...
Can Antiviral Therapy Prevent Liver Cancer in Patients With Chronic Hepatitis?
Chronic viral hepatitis is a major causative factor for hepatocellular carcinoma, but antiviral therapy might reduce the incidence of hepatocellular carcinoma by preventing or eliminating chronic hepatitis infections, according to Adrian M. Di Bisceglie, MD, Professor of Internal Medicine at Saint ...
Study Identifies How Cancer Cells May Develop Resistance to FGFR Inhibitors
A new study by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC– James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth...
Cisplatin-Based Chemotherapy in Pediatric Extracranial Malignant Germ Cell Tumors
In a study reported in the Journal of Clinical Oncology, Shaikh et al, of the Children’s Oncology Group, found that event-free survival rates were not maintained with the use of reduced and compressed cisplatin-based regimens in children and adolescents with intermediate-risk extracranial...
Osimertinib in EGFR Inhibitor–Pretreated T790M-Positive Advanced NSCLC
In the phase II extension component of the phase I/II AURA trial, reported by Yang et al in the Journal of Clinical Oncology, osimertinib (Tagrisso) was found to be highly active in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor–pretreated T790M-positive advanced...
Neoadjuvant Dual HER2 Blockade in HER2-Enriched Early Breast Cancer
In the Spanish phase II PAMELA study reported in The Lancet Oncology, Llombart-Cussac et al found that the HER2-enriched subtype was associated with the highest likelihood of pathologic complete response after neoadjuvant trastuzumab (Herceptin) and lapatinib (Tykerb) without chemotherapy in...
Ronald A. DePinho, MD, to Resign as President of MD Anderson
Ronald A. DePinho, MD, President of The University of Texas MD Anderson Cancer Center, has submitted a letter to Chancellor William H. McRaven of the University of Texas System tendering his resignation. Chancellor McRaven has asked Dr. DePinho to stay on through the end of the Texas Legislative...
Clinical Trials Actively Recruiting Patients With Colorectal Cancer
Phase I Study Title: A Pilot Study of SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine and Cyclophosphamide in Metastatic Colorectal Cancer as Maintenance Therapy Study Type: Phase I/interventional/parallel assignment Study Sponsor and Collaborators: Sidney Kimmel Comprehensive...
Scripps Florida Collaboration Awarded $3.3 Million to Develop Next-Generation Breast Cancer Therapies
A pair of scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded up to $3.3 million from the National Cancer Institute of the National Institutes of Health (NIH) to create the next generation of breast cancer treatments for the thousands of patients whose...
Expect Questions About the Cervical Cancer Mortality Study
A widely reported study found that cervical cancer mortality was higher and the racial disparity between black and white women greater than previously reported.1 The study omitted from the mortality estimates those women who had undergone hysterectomies, usually involving removal of the cervix....
Honoring the Life of Nancy E. Armitage
The University of Nebraska community mourns the loss of dedicated community leader and volunteer Nancy E. Armitage of Omaha. She died February 27, 2017, from complications associated with pancreatic cancer. Nancy is remembered for the support and encouragement she offered to others over the years...
Cervical Cancer Mortality Is Higher and Racial Disparity Wider Than Previously Reported
Cervical cancer mortality rates were significantly higher, particularly among black women, when national data were corrected to exclude women who have had hysterectomies. For black women, the cervical cancer mortality rate rose from 5.7 to 10.1 per 100,000 when corrected for hysterectomy, an...
Immunotherapy for Head and Neck Cancer: ‘The Fourth Modality Has Arrived’
“This is a big deal. This is going to change all of oncology, not just head and neck cancer,”1 Tanguy Seiwert, MD, remarked following a summary by Jeffrey Sosman, MD, on advances in immunotherapy for treating cancer.2 Dr. Sosman, Director of the Melanoma Program and Clinical Director of Cancer...
2017 Oncology Meetings
MARCH ESMO Symposium on Signaling Pathways in Cancer 2017March 17-18 • Barcelona, SpainFor more information: http://esmo.org/Conferences/Signalling-Pathways-2017 17th Multidisciplinary Management of Cancers: A Case-Based ApproachMarch 17-19 • Napa, CaliforniaFor more...
Immunotherapy Challenges in Lung Cancer: From Patient Selection to Clinical and Financial Toxicity
Immunotherapy has been a major advance in lung cancer, but it is not without its challenges, according to Sanjay Popat, PhD, FRCP, a consultant medical oncologist and reader in cancer medicine at the Royal Marsden Hospital, London, UK. He reviewed some of the challenges pertaining to the use of...
Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer
As reported by Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, Temple Health, and colleagues in The Lancet Oncology, pembrolizumab (Keytruda) has shown activity in patients in the locally advanced or metastatic urothelial carcinoma cohort included in the phase Ib KEYNOTE-012 trial. In the...
Addition of Cetuximab to Chemoradiotherapy for Anal Carcinoma
In a phase II trial (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group E3205) reported in the Journal of Clinical Oncology, Garg et al found that the addition of cetuximab (Erbitux) to definitive chemoradiotherapy appeared to reduce the rates of...
Germline Cancer Susceptibility Mutations in Early-Onset Colorectal Cancer
In a study reported in JAMA Oncology, Pearlman et al found that 16% of patients with early-onset colorectal cancer had germline cancer susceptibility mutations, with a wide array of such mutations being identified. Heather Hampel, MS, CGC, of The Ohio State University Comprehensive Cancer Center,...
Potential Biomarker of Recurrent Venous Thromboembolism in Patients Receiving Anticoagulants
In a biomarker analysis of the CATCH trial reported in the Journal of Clinical Oncology, Alok A. Khorana, MD, of the Cleveland Clinic, and colleagues found that elevated circulating tissue factor levels were associated with an increased risk of recurrent venous thromboembolism in cancer patients on ...
Expert Point of View: David R. Gandara, MD
“With the negative results of this phase III trial and the discontinuation of ganetespib development, is this the end for this once promising drug class in non–small cell lung cancer (NSCLC), or is there still an opportunity for heat shock protein (Hsp) inhibitors to make a meaningful impact?”...
FDA Approves Lenalidomide as Maintenance Therapy for Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
On February 22, the U.S. Food and Drug Administration (FDA) expanded the existing indication for lenalidomide (Revlimid) 10-mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant. Clinical Trial Findings The...
Cancer Has Aged Me
The news that I had breast cancer came at an especially difficult time in my life and was quite shocking to hear. My father had died of lung cancer just 1 month before my diagnosis, and I was still grieving his death when I suddenly had to confront my own mortality. In retrospect, the diagnosis...
No Improvement in Overall Survival With Addition of Ganetespib to Docetaxel in Patients With Non–Small Cell Lung Cancer
Despite positive results in the phase II GALAXY-1 study, the addition of ganetespib to docetaxel in the phase III GALAXY-2 study did not improve overall survival or progression-free survival in patients with advanced non–small cell lung cancer (NSCLC), according to data presented by Rathi Pillai,...
Eric D. Tetzlaff, MHS, PA-C, Receives National Recognition as AAPA Distinguished Fellow
Eric D. Tetzlaff, MHS, PA-C, a physician assistant at Fox Chase Cancer Center, has been recognized as a Distinguished Fellow of the American Academy of Physician Assistants (AAPA). He practices clinical care for patients with gastrointestinal cancers and sarcomas and has been at Fox Chase for most ...
An Oncologist’s Straightforward Guide for Women With Breast Cancer
If you Google the search term “breast cancer,” about 155,000,000 results will pop up in .83 seconds. Add to that pamphlets, journal articles, and library shelves bending under the weight of books written about breast cancer. That’s a mind-bending amount of information to parse through for the...
Expert Point of View: Kevin C. Oeffinger, MD
Kevin C. Oeffinger, MD, Director of the Adult Long-Term Follow-up Program at Memorial Sloan Kettering Cancer Center, New York, highlighted the typical fat distribution of this population while noting the limitations of standard criteria for metabolic syndrome, which include waist circumference....
Platinum Study Finds High Risk of Metabolic Syndrome in Testicular Cancer Survivors
A multicenter study of North American testicular cancer survivors treated with platinum-based chemotherapy has found a high prevalence of metabolic syndrome, a cluster of cardiovascular risk factors that doubles the risk of cardiovascular disease.1 According to the results of this trial,...
Building a Multidisciplinary Model of Care for Cancer Survivors
Last year’s inaugural Cancer Survivorship Symposium stressed the importance of bringing together the fields of medical oncology and primary care to ensure a coordinated effort to help patients with cancer transition to long-term survivorship care. Building on that goal, the 2017 Cancer Survivorship ...
ASCO and NCCN to Collaborate on Guidelines on Management of Immunotherapy Side Effects
ASCO and the National Comprehensive Cancer Network® (NCCN®) have announced a joint collaboration to publish practical clinical guidance on the management of side effects caused by immunotherapy. This novel collaboration aims to rapidly support improved quality of care for the growing number of...
Expert Point of View: Selina Luger, MD, Stephanie Lee, MD, and Gabriela Hobbs, MD
Speaking at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, before the hold on pacritinib was lifted (in January 2017), Selina Luger, MD, of the University of Pennsylvania, Philadelphia, commented, “I think the U.S. Food and Drug Administration (FDA) needs to revisit ...
Pacritinib Reduces Spleen Volume in Myelofibrosis
The investigational drug pacritinib met the primary endpoint of the phase III PERSIST-2 trial in high-risk patients with myelofibrosis and thrombocytopenia. Treatment with the Janus kinase (JAK)1/2 inhibitor pacritinib achieved a significant reduction in spleen volume compared with best available...
